Provided by Tiger Fintech (Singapore) Pte. Ltd.

TransCode Therapeutics Inc.

0.8148
+0.03484.46%
Pre-market: 0.7600-0.0548-6.73%04:37 EDT
Volume:1.76M
Turnover:1.39M
Market Cap:567.30K
PE:-0.01
High:0.8468
Open:0.8000
Low:0.7500
Close:0.7800
Loading ...

Company Profile

Company Name:
TransCode Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
8
Office Location:
6 Liberty Square,Suite 2382,Boston,Massachusetts,United States
Zip Code:
02109
Fax:
- -
Introduction:
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Directors

Name
Position
Philippe P. Calais
Independent Director, Chairman of the Board
Robert Michael Dudley
Co-Founder, President, Chief Executive Officer, Director
Erik Manting
Independent Director
Magda Marquet
Independent Director
Thomas A. Fitzgerald
Vice President, Chief Financial Officer, Director

Shareholders

Name
Position
Robert Michael Dudley
Co-Founder, President, Chief Executive Officer, Director
Thomas A. Fitzgerald
Vice President, Chief Financial Officer, Director